Exploring high-resolution neurochemical imaging for epilepsy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031840

Enrollment

Registered

2023-05-15

Start date

2024-01-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G40.0

Interventions

Group 1: Pilot study for new/improved imaging techniques - descriptive analysis of a patient cohort. Method development: 30 adult healthy volunteers (15 for method development based on previous meth

classified as low confidence by neuroradiologists) that offer orientation points and the second consists of MRN cases. Parameters recorded: Morphological MRI images, imaging of metabolite concentrati

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: informed consent; for pharmacoresistant epilepsy as defined by the International League against Epilepsy (ILAE) / healthy controls: no pathological findings on MRI or any known history of neurological disorders or medical treatment

Exclusion criteria

Exclusion criteria: contraindications for 7T MR imaging (claustrophobia, ferromagnetic metal implants, weight <30 kg); no pregnancy; no recent head/brain surgery.

Design outcomes

Primary

Measure	Time frame
1- Improved robustness of 7T high-resolution MRSI Implementation of motion correction for 7T HR MRSI based on existing strategies without increased measurement time. Development of custom B0-shimming software solutions for extended MRSI brain coverage and improved spectral quality. Performance Targets: Comparison data about the performance of both motion correction strategies; operational custom shim software; mean reduction of neurochemical linewidths (estimated using water linewidth, aiming for a mean of 10 Hz, which is defined as excellent quality by community consensus (49)) over the whole brain and within epilepsy ROIs (e.g., temporal lobe, hippocampus); total MRSI duration of = 15 min; 2- Pilot study for 7T high-resolution MRSI for epilepsy Acquisition of fast whole-brain 7T HR MRSI in a cohort of epilepsy patients (sub cohorts: FCD, hippocampal sclerosis, ganglioglioma) and healthy controls. Comparison of neurochemical profiles to literature and healthy volunteers. Performance Targets: 60 patient and 15 healthy control MRSI data sets; good quality (>80% of the brain fitted with quality criteria as defined in WP2 - Evaluation and quality assurance, evaluated impact of lipid residuals) images for at least six neurochemicals (e.g., NAA, Cr, Cho, Glu, Gln, Ins); identification of focal and network alterations compared to the healthy cohort based on mean concentration estimate changes in defined brain ROIs; 3- Comparison of neurochemical maps to the diagnostic gold standard Comparison of MRSI-derived neurochemical maps to the diagnostic gold standard (routine MRI, EEG, histopathology). Performance Targets: Correlation of neurochemical findings to the diagnostic gold standard; assessed diagnostic sensitivity and specificity of epileptogenic lesion detection for the addition of neurochemical imaging to presurgical MRI;	—

Measure

Time frame

1- Improved robustness of 7T high-resolution MRSI Implementation of motion correction for 7T HR MRSI based on existing strategies without increased measurement time. Development of custom B0-shimming software solutions for extended MRSI brain coverage and improved spectral quality. Performance Targets: Comparison data about the performance of both motion correction strategies; operational custom shim software; mean reduction of neurochemical linewidths (estimated using water linewidth, aiming for a mean of 10 Hz, which is defined as excellent quality by community consensus (49)) over the whole brain and within epilepsy ROIs (e.g., temporal lobe, hippocampus); total MRSI duration of = 15 min; 2- Pilot study for 7T high-resolution MRSI for epilepsy Acquisition of fast whole-brain 7T HR MRSI in a cohort of epilepsy patients (sub cohorts: FCD, hippocampal sclerosis, ganglioglioma) and healthy controls. Comparison of neurochemical profiles to literature and healthy volunteers. Performance Targets: 60 patient and 15 healthy control MRSI data sets; good quality (>80% of the brain fitted with quality criteria as defined in WP2 - Evaluation and quality assurance, evaluated impact of lipid residuals) images for at least six neurochemicals (e.g., NAA, Cr, Cho, Glu, Gln, Ins); identification of focal and network alterations compared to the healthy cohort based on mean concentration estimate changes in defined brain ROIs; 3- Comparison of neurochemical maps to the diagnostic gold standard Comparison of MRSI-derived neurochemical maps to the diagnostic gold standard (routine MRI, EEG, histopathology). Performance Targets: Correlation of neurochemical findings to the diagnostic gold standard; assessed diagnostic sensitivity and specificity of epileptogenic lesion detection for the addition of neurochemical imaging to presurgical MRI;

—

Secondary

Measure	Time frame
see Primary Endpoint	—

Countries

Austria

Contacts

Public ContactGilbert Hangel

Medizinische Universität Wien

gilbert.hangel@meduniwien.ac.at+4314040064710

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026